Edition:
India

Agios Pharmaceuticals Inc (AGIO.OQ)

AGIO.OQ on NASDAQ Stock Exchange Global Select Market

91.06USD
20 Jul 2018
Change (% chg)

-- (--)
Prev Close
$91.06
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
142,097
52-wk High
$99.77
52-wk Low
$51.66

Chart for

About

Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company's cancer product candidates are... (more)

Overall

Beta: 1.94
Market Cap(Mil.): $3,409.16
Shares Outstanding(Mil.): 48.39
Dividend: --
Yield (%): --

Financials

Agios Pharmaceuticals leukemia drug gets U.S. approval

Agios Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration approved its treatment for a type of leukemia, the first targeted drug for patients with a specific genetic mutation.

20 Jul 2018

UPDATE 1-Agios Pharmaceuticals leukemia drug gets U.S. approval

July 20 Agios Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration approved its treatment for a type of leukemia, the first targeted drug for patients with a specific genetic mutation.

20 Jul 2018

FDA approves Agios Pharmaceuticals leukemia drug

July 20 Agios Pharmaceuticals Inc said on Friday its oral drug to treat a type of leukemia was approved by the U.S. health regulator.

20 Jul 2018

BRIEF-Agios Qtrly Loss Per Share $1.63

* AGIOS PROVIDES BUSINESS UPDATE ON DISCOVERY RESEARCH STRATEGY AND PIPELINE, PROGRESS ON CLINICAL PROGRAMS, COMMERCIAL LAUNCH PREPARATIONS AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AT INVESTOR DAY

04 May 2018

BRIEF-Agios Says First Patient Dosed In Lymphoma Study

* AGIOS ANNOUNCES FIRST PATIENT DOSED WITH MAT2A INHIBITOR AG-270 IN PHASE 1 STUDY IN PATIENTS WITH ADVANCED SOLID TUMORS OR LYMPHOMA WITH AN MTAP DELETION Source text for Eikon: Further company coverage:

19 Mar 2018

BRIEF-Agios Reports Qtrly Loss Per Share $1.81

* AGIOS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

14 Feb 2018

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $37.33 -0.03
Novartis AG (NOVN.S) CHF81.84 -0.36
Roche Holding Ltd. (ROG.S) CHF232.30 -1.70
Roche Holding Ltd. (RO.S) CHF236.60 -2.00
Sanofi SA (SASY.PA) €72.03 -0.33
AstraZeneca plc (AZN.L) 5,551.00 -38.00
GlaxoSmithKline plc (GSK.L) 1,558.09 +8.29
Eli Lilly And Co (LLY.N) $88.47 -0.96
Shire PLC (SHP.L) 4,356.00 -26.50
Shire PLC (3159084.L) -- --

Earnings vs. Estimates